A Multi-center 12-week Study of HMS5552 in T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 258 participants.

Also called NCT02561338

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 258 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02561338
Other papers using this trial's data
  • Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study The lancet. Diabetes & endocrinology, 2018-08 DOI, PubMed 29735394 PubMed links an erratum for this paper. Erratum: PMID 29754897

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02561338. Randomized; quadruple masking; primary purpose treatment. Start 2015-09 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2020-03-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multi-center 12-week Study of HMS5552 in T2DM
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HMS5552
Intervention (Drug)
HMS5552
Intervention (Drug)
HMS5552
Intervention (Drug)
HMS5552
Intervention (Other)
Placebo
Lead sponsor
Hua Medicine Limited (class: industry)
Collaborator
Tigermed Consulting Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02561338
Content hash
2d182d2c88aa42fe07c10d64c9cfc915c77dfe766afe9da3f3f601c2f34b734c